×

Tag: Glucosepane

Longevity Therapeutics banner
We continue our coverage of Longevity Therapeutics 2021 and bring you part 2 of day 1. Dr. Steven Braithwhite - Chief Scientific Officer, Alkahest Steven Braithwhite from Alkahest gave an update on the company’s ongoing clinical trials. Alkahest has been sifting plasma proteome in search for proteins that decrease or increase with age (read our...
Blood cells in an artery
Today, we want to highlight the results of a recent long-term study, which collected data over a four-year period to investigate the link between aortic stiffening and cognitive decline, including dementia. During aging, our blood vessels become increasingly stiff and lose their flexibility, and the cells comprising it struggle to contract and relax properly. Blood...
Collagen
New research takes us a step close to finding ways to remove the advanced glycation end-product known as glucosepane, a likely reason why our arteries stiffen as we age. Advanced Glycation End-ProductsIt has been proposed for some time that one reason we age is the accumulation of sugary metabolic wastes known as advanced glycation end-products...
Interview with Alexander Fedintsev
Two researchers, Alexander Fedintsev and Alexey Moskalev, have published an expansive review paper in which they propose a new hallmark of aging [1]. The authors draw our attention to a phenomenon that is sometimes overlooked in the context of aging: the accumulation of damage to long-lived molecules caused by the non-enzymatic chemical reactions of glycation,...
Three buildings
There are lots of exciting companies working in the aging field, and it's a great time to tell you about three of the more interesting ones. Most of these companies are a while away from human trials yet, but their innovations could possibly be truly game changing. Underdog Pharma Underdog Pharmaceuticals is a spin-off company...
Collagen
Some pleasant news has recently arrived: Revel Pharmaceuticals has successfully completed a seed round in order to begin developing therapeutics that target glucosepane crosslinks, which are a proposed reason why we age, develop diseases such as diabetes, and suffer from stiffened arteries and hypertension. In the business of startups, a seed round refers to a...